ALECR.PA Eurofins-Cerep SA
- Market cap
- EUR 92.8M
- P/E
- 11.9x
- P/B
- 1.14x
- ROE
- 6.3%
- Dividend yield
- -
- Fundamental score
- 3.3/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ALECR.PA undervalued?
Graham numberALECR.PA trades 22.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eurofins-Cerep SA fundamental analysis
8 of 11 checks passedROE 2/2
ROE surpassing expectations (22.53%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.
ROA 2/2
This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.
PBV 1/2
The stock's PBV ratio (2.22x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.
DER 2/2
The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.
Revenue Growth 1/2
Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.
Net Profit Growth 2/2
This company has consistently achieved strong net profit growth over the past five years, demonstrating a solid financial performance and making it an appealing investment option.
Assets Growth 2/2
With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.
Graham Number 0/1
The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.
Dividend Growth 0/2
The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.
Dividend 0/2
Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.
Buffet Intrinsic Value 1/1
Based on Warren Buffett's formula, the company's stock appears undervalued (134.622), presenting an attractive investment chance with its intrinsic value surpassing the current market price.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Eurofins-Cerep SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eurofins-Cerep SA
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company also provides research services, including compound management, and high-throughout screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and is based in Celle-Lévescault, France. Eurofins-Cerep SA is a sub…
Full company profileEurofins-Cerep SA financial statements
Eurofins-Cerep SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 23.4M | 24.4M | 25.5M | 31.0M | 32.7M | 41.6M | 47.6M | 44.1M | 40.5M | 41.0M |
| Gross Profit | 11.6M | 12.8M | 12.5M | 14.5M | 15.8M | 20.8M | 23.6M | 20.2M | 17.5M | 6.79M |
| Operating Income | 1.63M | 4.37M | 4.98M | 4.23M | 5.54M | 10.1M | 11.5M | 6.46M | 4.50M | 2.87M |
| EBITDA | 2.89M | 4.69M | 4.03M | 5.24M | 6.30M | 10.7M | 12.9M | 9.10M | 8.89M | 5.23M |
| Net Income | 2.49M | 3.85M | 3.86M | 4.37M | 5.58M | 9.84M | 11.5M | 7.64M | 7.15M | 4.78M |
| EPS | 493 | 814 | 765 | 866 | 1,106 | 1,951 | 2,285 | 1,514 | 1,418 | 948 |
| Balance Sheet | ||||||||||
| Total Assets | 25.9M | 30.2M | 35.3M | 40.0M | 46.1M | 59.7M | 71.0M | 79.2M | 84.1M | 88.8M |
| Total Liabilities | 8.49M | 8.87M | 10.1M | 10.4M | 10.9M | 14.4M | 14.1M | 14.6M | 12.3M | 12.4M |
| Shareholders' Equity | 17.5M | 21.3M | 25.2M | 29.5M | 35.1M | 45.4M | 56.9M | 64.6M | 71.7M | 76.4M |
| Cash & Short-term Investments | 3.92M | 1.45M | 783K | 3.34M | 4.90M | 1.30M | 12.8M | 8.63M | 17.6M | 21.0M |
| Total Debt | - | 346K | 301K | 5.15K | 20.0K | 18.9K | 4.83K | 3.44K | 329K | 7.68K |
| Cash Flow | ||||||||||
| Operating Cash Flow | 5.59M | 4.24M | - | - | - | - | - | - | - | - |
| Capital Expenditure | 5.67M | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -72.9K | 3.18M | - | - | - | - | - | - | - | - |
| Ratios | ||||||||||
| ROE | 14.2% | 18.1% | 15.3% | 14.8% | 15.9% | 21.7% | 20.2% | 11.8% | 10.0% | 6.3% |
| ROA | 9.6% | 12.8% | 10.9% | 10.9% | 12.1% | 16.5% | 16.2% | 9.6% | 8.5% | 5.4% |
| Net Profit Margin | 10.6% | 15.8% | 15.2% | 14.1% | 17.1% | 23.7% | 24.2% | 17.3% | 17.7% | 11.7% |
| Debt to Equity | - | 0.02x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eurofins-Cerep SA dividends
Eurofins-Cerep SA has not paid dividends in the last 10 fiscal years.
Last stock split: 1:50 on Jul 27, 2017.
Who owns Eurofins-Cerep SA
- Insiders 95.78%
- Institutions 0.00%
- Public & others 4.22%
- Shares outstanding 5.04K
Eurofins-Cerep SA company profile
- Company name
- Eurofins-Cerep SA
- Ticker
- ALECR.PA
- ISIN
- FR0013256518
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 211
- Fiscal year end
- December
- Address
- 2 rue du professeur GargouIl, Celle-Lévescault, France, 86600
- Phone
- 33 5 49 89 30 00
- Website
- eurofins.fr/cerep
About Eurofins-Cerep SA
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company also provides research services, including compound management, and high-throughout screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and is based in Celle-Lévescault, France. Eurofins-Cerep SA is a subsidiary of Eurofins Discovery Services LUX Holding SARL.
Eurofins-Cerep SA management
2- Mr. Damien VielliardCEO & Director · born 1977
- Ms. Sophie MacaultGeneral Counsel & Corporate Secretary